Brofaromine

Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA) and a 5-HT reuptake inhibitor that was investigated for its potential use in the treatment of depression and anxiety disorders. Despite showing promise in clinical trials, brofaromine has not been widely marketed or approved for medical use in many countries. Its chemical structure and mechanism of action share similarities with other antidepressants, but its unique properties as a RIMA make it of particular interest in psychiatric pharmacology.

Mechanism of Action

Brofaromine acts primarily by inhibiting the enzyme monoamine oxidase A (MAO-A), which is responsible for the breakdown of monoamines such as serotonin, norepinephrine, and dopamine. By inhibiting this enzyme, brofaromine increases the levels of these neurotransmitters in the brain, which can help improve mood and alleviate symptoms of depression. Unlike non-selective monoamine oxidase inhibitors (MAOIs), brofaromine selectively targets MAO-A, reducing the risk of hypertensive crisis associated with dietary tyramine intake, a serious side effect of older MAOIs. Additionally, its ability to inhibit the reuptake of serotonin contributes to its antidepressant effects.

Clinical Uses

Brofaromine was primarily investigated for its potential in treating major depressive disorder (MDD) and various anxiety disorders. Clinical trials have demonstrated its efficacy in reducing depressive symptoms, with an advantage of having a more favorable side effect profile compared to traditional MAOIs and some tricyclic antidepressants (TCAs). Its anxiolytic effects also suggested potential use in treating social anxiety disorder and panic disorder, but further research was needed to fully establish its effectiveness and safety for these conditions.

Pharmacokinetics

The pharmacokinetic profile of brofaromine includes oral administration with good absorption. It is metabolized in the liver and has a relatively short half-life, which necessitates daily dosing to maintain therapeutic levels. The drug's metabolism and excretion pathways suggest that dose adjustments may be necessary in patients with hepatic impairment, but its overall pharmacokinetics are considered favorable for an antidepressant.

Adverse Effects

Brofaromine is generally well tolerated, with fewer dietary restrictions compared to non-selective MAOIs due to its selectivity for MAO-A. However, it can still cause some adverse effects, including insomnia, nausea, dizziness, and headaches. The risk of serotonin syndrome, a potentially life-threatening condition, may be increased if brofaromine is combined with other serotonergic drugs.

Current Status

As of the last update, brofaromine has not been approved for clinical use in the United States, European Union, or many other regions. Its development was discontinued for reasons that are not entirely clear but may include commercial considerations or the emergence of other antidepressants with similar or better efficacy and safety profiles. Despite its limited availability, research on brofaromine contributes to the understanding of RIMAs and their potential role in treating mood and anxiety disorders.

See Also

• Monoamine oxidase inhibitor
• Depression
• Anxiety disorder
• Serotonin

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian